IL282485B2 - Compositions containing an mdm2 inhibitor and a cka1 inhibitor and/or an mdm4 inhibitor for use in the treatment of tumors with non-mutant p53 - Google Patents
Compositions containing an mdm2 inhibitor and a cka1 inhibitor and/or an mdm4 inhibitor for use in the treatment of tumors with non-mutant p53Info
- Publication number
- IL282485B2 IL282485B2 IL282485A IL28248521A IL282485B2 IL 282485 B2 IL282485 B2 IL 282485B2 IL 282485 A IL282485 A IL 282485A IL 28248521 A IL28248521 A IL 28248521A IL 282485 B2 IL282485 B2 IL 282485B2
- Authority
- IL
- Israel
- Prior art keywords
- composition
- tumor
- inhibitor
- lenalidomide
- mdm4
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752382P | 2018-10-30 | 2018-10-30 | |
| PCT/US2019/058319 WO2020092221A1 (en) | 2018-10-30 | 2019-10-28 | Method of treatment of p53 wt tumors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL282485A IL282485A (en) | 2021-06-30 |
| IL282485B1 IL282485B1 (en) | 2025-05-01 |
| IL282485B2 true IL282485B2 (en) | 2025-09-01 |
Family
ID=68582462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL282485A IL282485B2 (en) | 2018-10-30 | 2019-10-28 | Compositions containing an mdm2 inhibitor and a cka1 inhibitor and/or an mdm4 inhibitor for use in the treatment of tumors with non-mutant p53 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12115151B2 (https=) |
| EP (1) | EP3873460B1 (https=) |
| JP (2) | JP7653907B2 (https=) |
| KR (1) | KR102879859B1 (https=) |
| CN (1) | CN112996503A (https=) |
| AU (1) | AU2019369216B2 (https=) |
| CA (1) | CA3115716A1 (https=) |
| ES (1) | ES2986421T3 (https=) |
| IL (1) | IL282485B2 (https=) |
| WO (1) | WO2020092221A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| CN115216514B (zh) * | 2022-08-01 | 2026-03-17 | 中国科学技术大学 | Vam6（Vps39）作为靶点在药物筛选、基因编辑以及疾病治疗中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX388093B (es) * | 2016-11-15 | 2025-03-19 | Novartis Ag | Dosis y regimen para inhibidores de la interaccion hdm2-p53. |
-
2019
- 2019-10-28 WO PCT/US2019/058319 patent/WO2020092221A1/en not_active Ceased
- 2019-10-28 KR KR1020217015953A patent/KR102879859B1/ko active Active
- 2019-10-28 JP JP2021522967A patent/JP7653907B2/ja active Active
- 2019-10-28 IL IL282485A patent/IL282485B2/en unknown
- 2019-10-28 AU AU2019369216A patent/AU2019369216B2/en active Active
- 2019-10-28 US US17/289,122 patent/US12115151B2/en active Active
- 2019-10-28 ES ES19805046T patent/ES2986421T3/es active Active
- 2019-10-28 CA CA3115716A patent/CA3115716A1/en active Pending
- 2019-10-28 CN CN201980070367.1A patent/CN112996503A/zh active Pending
- 2019-10-28 EP EP19805046.0A patent/EP3873460B1/en active Active
-
2024
- 2024-10-24 JP JP2024187067A patent/JP2025026846A/ja active Pending
Non-Patent Citations (5)
| Title |
|---|
| LIAO GUOCHAO ET AL,, THE DEVELOPMENT OF PIPERIDINONES AS POTENT MDM2-P53 PROTEIN-PROTEIN INTERACTION INHIBITORS FOR CANCER THERAPY, 18 September 2018 (2018-09-18) * |
| LINDNER STEFANIE ET AL,, THE MOLECULAR MECHANISM OF THALIDOMIDE ANALOGS IN HEMATOLOGIC MALIGNANCIES, 5 August 2016 (2016-08-05) * |
| MAXIMILIAN STAHL ET AL,, LENALIDOMIDE USE IN MYELODYSPLASTIC SYNDROMES: INSIGHTS INTO THE BIOLOGIC MECHANISMS AND CLINICAL APPLICATIONS : USE OF LENALIDOMIDE IN MDS: BIOLOGY AND EFFICACY, 13 February 2017 (2017-02-13) * |
| PAOLA SECCHIERO ET AL,, RECENT ADVANCES IN THE THERAPEUTIC PERSPECTIVES OF NUTLIN-3, 1 February 2011 (2011-02-01) * |
| TOLEDO ET AL,, MDM2 AND MDM4: P53 REGULATORS AS TARGETS IN ANTICANCER THERAPY, 10 July 2007 (2007-07-10) * |
Also Published As
| Publication number | Publication date |
|---|---|
| US12115151B2 (en) | 2024-10-15 |
| JP7653907B2 (ja) | 2025-03-31 |
| WO2020092221A1 (en) | 2020-05-07 |
| IL282485B1 (en) | 2025-05-01 |
| US20210379039A1 (en) | 2021-12-09 |
| EP3873460A1 (en) | 2021-09-08 |
| AU2019369216A1 (en) | 2021-05-20 |
| JP2022505884A (ja) | 2022-01-14 |
| AU2019369216B2 (en) | 2022-05-19 |
| JP2025026846A (ja) | 2025-02-26 |
| KR20210087958A (ko) | 2021-07-13 |
| ES2986421T3 (es) | 2024-11-11 |
| EP3873460B1 (en) | 2024-06-12 |
| KR102879859B1 (ko) | 2025-11-04 |
| CN112996503A (zh) | 2021-06-18 |
| CA3115716A1 (en) | 2020-05-07 |
| IL282485A (en) | 2021-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhou et al. | PD-L1: expression regulation | |
| Cufi et al. | Autophagy positively regulates the CD44+ CD24-/low breast cancer stem-like phenotype | |
| Abraha et al. | Apoptotic pathways as a therapeutic target for colorectal cancer treatment | |
| Synnott et al. | Mutant p53: a novel target for the treatment of patients with triple‐negative breast cancer? | |
| Agnarelli et al. | IRF4 in multiple myeloma—Biology, disease and therapeutic target | |
| Duffy et al. | p53 as a target for the treatment of cancer | |
| Crombet Ramos et al. | Nimotuzumab for patients with inoperable cancer of the head and neck | |
| Camicia et al. | BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNγ–STAT1–IRF1–p53 axis in diffuse large B-cell lymphoma | |
| JP2024074801A5 (https=) | ||
| Hoffmann | Systemic therapy strategies for head-neck carcinomas: Current status | |
| BR112022008534A2 (pt) | Compostos, composição farmacêutica, conjugado e métodos para tratar câncer e para tratar um distúrbio relacionado à proteína ras | |
| Bullard Dunn et al. | Evolving therapies and FAK inhibitors for the treatment of cancer | |
| Kumar et al. | Current therapeutic strategies and challenges in NSCLC treatment: A comprehensive review | |
| IL282485B1 (en) | Compositions containing an MDM2 inhibitor and a CKa1 inhibitor and/or an MDM4 inhibitor for use in the treatment of tumors with non-mutant p53 | |
| US20160122408A1 (en) | Galectin-3 Inhibitor (Gal-3M) is Associated with Additive Anti-Myeloma and Anti-Solid Tumor Effects, Decreased Osteoclastogenesis and Organ Protection when Used in Combination with Proteasome Inhibitors | |
| Lei et al. | A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro | |
| Weekes et al. | Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors | |
| Djerf et al. | ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839) | |
| Ge et al. | Synergistic antitumor effects of CDK inhibitor SNS‑032 and an oncolytic adenovirus co‑expressing TRAIL and Smac in pancreatic cancer | |
| Iizuka et al. | APOBEC 3G is increasingly expressed on the human uterine cervical intraepithelial neoplasia along with disease progression | |
| Bai et al. | Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer | |
| Aguirre-Hernández et al. | Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad∆∆ through Bcl-2-dependent attenuation of autophagy | |
| Tomao et al. | Cervical cancer: are there potential new targets? An update on preclinical and clinical results | |
| Kim et al. | Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification | |
| Teng et al. | The complexity of DEK signaling in cancer progression |